# PRESS RELEASE

**International Data Serving Digestive Oncologists**
**A Major Advancement in the Stratification of Metastatic Colorectal Cancer**

*Paris, June 2025*

Renowned worldwide for the quality of its databases, the A.R.CA.D Foundation centralizes several million data points from international, academic, and industry-sponsored clinical trials in digestive oncology.

Each year, it publishes key scientific studies in collaboration with leading experts in metastatic colorectal cancer. Based on this unique dataset, it has developed a robust and reliable prognostic model, now published in the Journal of Clinical Oncology, the flagship journal of the American Society of Clinical Oncology (May 2025).

## A Study Based on Data from 37,560 Patients

The analysis includes 48 randomized trials involving 37,560 patients treated in 1st, 2nd, and 3rd lines of chemotherapy ± targeted therapy for metastatic colorectal cancer (each "line" refers to a specific chemotherapy protocol). The primary endpoint was overall survival.

A unique multivariate model was developed using seven independent clinical variables:

- ECOG Performance Status (PS)
- Hemoglobin (HGB)
- Platelet count (PLT)
- White Blood Cell / Neutrophil Ratio (WBC/ANC)
- LDH
- Alkaline Phosphatase (ALP)
- Number of metastatic sites

These variables enabled the creation of the OPS (Oncology Prognostic Score), a stratification tool defining four patient subgroups with significantly distinct prognoses for each treatment line. Validated by adequate C-indices, the model proves to be robust and consistent across all therapeutic lines.

## SPOD: An Online Tool to Help Oncologists Choose the Best Treatment Option

To facilitate practical implementation of these results, the Foundation developed SPOD (Score Pronostic Oncology Digestive), a free-to-use Progressive Web Application.

> A PWA functions like a mobile app: fast, fluid, and accessible from any connected device— no download required.

From the Foundation's website, oncologists can enter a patient's clinical and biological variables and, in just a few clicks, receive an estimate of median survival based on the OPS subgroup to which the patient belongs.

> *"With this new application, the Foundation combines secondary research with therapeutic decision-making. This app, dedicated to digestive oncologists specialized in colorectal cancer, is a first; A.R.CA.D's ambition is to develop similar tools for other digestive cancers."*
>
> Pr Jean-Baptiste Bachet – Member of ARCAD Colorectal Database

This model, based on simple parameters readily available in routine care, enables:
- Better patient stratification in future clinical trials, reducing potential analysis bias;
- Objective support for treatment decisions, improving benefit-risk estimations for each therapeutic line;
- Significant time savings during consultations.

**SPOD is a valuable tool for both therapeutic decision-making in clinical practice and clinical research, allowing for more accurate prognosis assessments before each treatment line.**



Publication : https://ascopubs.org/doi/10.1200/JCO-24-01968
Application : https://www.fondationarcad.org/en/spod-app/

Contact : Ségolène de Retz – General manager

*About A.R.CA.D Foundation*

*Founded in 2006 by Professor Aimery de Gramont and chaired since October 2022 by Professor Thierry André, Head of Oncology at Saint-Antoine Hospital, the A.R.CA.D Foundation is the only public-interest foundation in France dedicated exclusively to digestive cancers. Governed by a board of 10 volunteer members and a government commissioner, its mission is to initiate and/or fund projects related to its social objectives: Research, Information, and Prevention.*

*The Foundation is the only entity with individual patient databases (nearly 100,000 patients) from international clinical trials in metastatic colorectal and pancreatic cancer, sponsored by either industry or academic institutions. Over sixty scientific articles based on research using these datasets have been published in international journals.*

Fondation A.R.CA.D – Aide et Recherche en Cancérologie Digestive
45 rue de Croulebarbe 75013 Paris | Siège social : 4 rue Kleber - 92300 Levallois Perret
Tél. : + 33 1 47 31 69 19 - contact@fondationarcad.org - **www.fondationarcad.org**
N° SIRET 493 768 030 00030